Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers

This study has been completed.
Sponsor:
Collaborator:
Endocyte
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00507741
First received: July 24, 2007
Last updated: September 19, 2013
Last verified: September 2013

July 24, 2007
September 19, 2013
August 2007
July 2009   (final data collection date for primary outcome measure)
Part A: Percentage of patients deriving clinical benefit. Part B: To gather pilot data on efficacy and toxicity of EC145. [ Time Frame: Clinical benefit is defined as the ability to receive 6 or more cycles (i.e., months) of therapy without progression of disease. ] [ Designated as safety issue: No ]
Percentage of patients deriving clinical benefit. [ Time Frame: Clinical benefit is defined as the ability to receive 6 or more cycles of therapy without progression of disease. ]
Complete list of historical versions of study NCT00507741 on ClinicalTrials.gov Archive Site
  • Tumor responses to EC145 therapy. [ Time Frame: Duration of EC145 therapy will vary according to individual patient response. ] [ Designated as safety issue: No ]
  • Progression-free survival, response duration, and overall survival time observed after EC145 therapy. [ Time Frame: 2 years after completing therapy with EC145 and the 30-day follow-up period. ] [ Designated as safety issue: No ]
  • Tumor responses to EC145 therapy. [ Time Frame: Duration of EC145 therapy will vary according to individual patient response. ]
  • Time-to-progression, response duration, and overall survival time observed after EC145 therapy. [ Time Frame: 2 years after completing therapy with EC145 and the 30-day follow-up period. ]
Not Provided
Not Provided
 
Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers
Protocol EC-FV-02: A Phase II Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers

This is a Phase II clinical trial evaluating the benefit from therapy with EC145 in patients with advanced ovarian and endometrial cancers.

This is a Phase II clinical trial of EC145 administered to patients with advanced ovarian and endometrial cancers.

EC145 is a drug that is specifically designed to enter cancer cells via the folate vitamin receptor (FR). Experimental evidence shows that this target receptor is expressed on virtually all ovarian cancers as well as the majority of endometrial cancers. Early clinical evidence in a small number of Phase I patients suggests that EC145 may have antitumor effect in women with advanced ovarian cancer and that it is generally well-tolerated. This evidence suggests that EC145 may be useful as chemotherapy against advanced ovarian and endometrial cancers. The primary objective of Part A of this study is to collect data on clinical benefit produced by therapy with EC145. The primary objective of Part B of this study is to collect data on the safety and efficacy of EC145.

All patients will undergo imaging with the FR targeting investigational imaging agent EC20(FolateScan) during the screening period to confirm eligibility for the treatment portion of the clinical trial. Clinical evidence suggests that EC20 may be used to identify women with cancers that express the target receptor.

Information about the safety and tolerability of both EC145 and EC20 will be assessed.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Ovarian Cancer
  • Endometrial Cancer
Drug: EC145

Part A (enrollment complete): Induction Phase: EC145 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: EC145 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, patients may receive EC145 via an ambulatory pump after the first week of therapy has been administered in the clinic setting.

Part B (enrollment completed): EC145 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, patients may receive EC145 via an ambulatory pump after the first week of therapy has been administered in the clinic setting.

Experimental: 1

Part A (enrollment complete): Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) CT, patient may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Patients continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined maximum benefit.

Part B (enrollment complete): 4-week cycles with CT every 8 weeks. Patients continue on cycle until they experience disease progression, unacceptable toxicity, or attain protocol-defined maximum benefit.

Intervention: Drug: EC145
Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007 May 1;67(9):4434-42.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
June 2011
July 2009   (final data collection date for primary outcome measure)

Part A (enrollment complete):

Inclusion Criteria:

  • Radiographic evidence of measurable disease (by RECIST criteria) and either:

    • Advanced epithelial ovarian cancer with serous or endometrioid histology, as confirmed by previous biopsy or,
    • EC20 positive ovarian cancer, primary peritoneal cancer or adenocarcinoma of the endometrium.
  • Prior treatment with platinum and/or taxane compounds.
  • ECOG Performance status of 0-2.
  • At least 4 weeks from prior therapy and recovered from associated acute toxicities.
  • Adequate bone marrow reserve, renal, and hepatic function.
  • Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.

Exclusion Criteria:

  • Serious comorbidities (as determined by the Principal Investigator).
  • Women who are pregnant or lactating.
  • Symptomatic CNS metastasis.
  • Prior radiation therapy to assessable disease, unless disease progression is confirmed at that site.
  • Requires palliative radiotherapy at time of study entry.
  • Unable to tolerate conditions for radionuclide imaging.
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.
  • Patients who have been administered another radiopharmaceutical that would interfere with the assessment of 99mTc-EC20.

Part B (currently recruiting):

Inclusion Criteria:

  • Radiographic evidence of measurable disease (by RECIST criteria)
  • EC20 positive recurrent or persistent epithelial ovarian, primary fallopian tube, or peritoneal cancer.
  • Prior treatment with platinum compounds, but not more than 4 prior cytotoxic chemotheraputic regimens.
  • ECOG Performance status of 0-2.
  • At least 3 weeks from prior cytotoxic therapy and recovered from associated acute toxicities.
  • Adequate bone marrow reserve, renal, and hepatic function.
  • Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.

Exclusion Criteria:

  • Serious comorbidities (as determined by the Principal Investigator).
  • Women who are pregnant or lactating.
  • Symptomatic CNS metastasis.
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.
  • Patients who have had prior therapy with Vinorelbine or vinca-containing compounds.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00507741
8109-007, EC-FV-02
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Endocyte
Study Director: Richard A Messmann, MD, MHS, MSc Endocyte
Merck Sharp & Dohme Corp.
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP